Ascendis Pharma A/S (ASND) Stock Analysis
Verdict: WATCH (do not buy)
TransCon commercial expansion drives revenue growth, but repeated EPS misses and high debt present execution risk.
Investment score: 59/100
Analysis as of
Is Ascendis Pharma A/S stock worth reviewing? The TradeMates thesis
Commercial expansion yields 113% revenue growth and positive FCF, but persistent quarterly EPS misses and debt balance the bullish pipeline thesis.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 72/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 75/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 58/100 (weight 15%)
Ascendis Pharma A/S opportunities and risks
What speaks for ASND
- TransCon Platform Commercial Scaling
What speaks against ASND
- Persistent Quarterly Earnings Misses
Peers and competitors
- GMAB.CO
- ZEAL.CO
- BAVA.CO
- SANION.ST
- BIOPOR.CO
Frequently asked questions about Ascendis Pharma A/S (ASND)
Is ASND stock a good investment?
The TradeMates model rates Ascendis Pharma A/S as WATCH (do not buy) with an investment score of 59/100. Commercial expansion yields 113% revenue growth and positive FCF, but persistent quarterly EPS misses and debt balance the bullish pipeline thesis. This is algorithmic model output, not personal investment advice.
Is ASND stock a buy?
The TradeMates model verdict for ASND is WATCH (do not buy) with an investment score of 59/100. Treat this as a model signal to review, not a personal buy recommendation.